SHERIDAN, WYOMING – May 7, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a leading medical technology company, has announced the appointment of Patrick Daly as its new Chief Business Officer. Daly, a seasoned veteran with over 30 years of experience in the healthcare industry, will play a crucial role in driving business growth and enhancing Terumo BCT's strategic initiatives.

With a distinguished career in business development and strategic partnerships, Daly brings valuable expertise to the company as it continues to expand its portfolio of solutions for blood collection, therapeutic apheresis, and cell therapy. His leadership is expected to accelerate Terumo BCT's goals for innovation, market integration, and enterprise expansion.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive (NASDAQ: ISRG), a global leader in robotic-assisted surgery, today announced the U.S. Food and Drug Administration (FDA) has granted clearance for its da Vinci Single Port (SP) surgical system for transanal local excision/resection. This clearance, which builds upon previous FDA approvals for transabdominal colorectal procedures, further enhances the capabilities of the da Vinci SP system, supporting minimally invasive surgery via natural orifice access.

Advancing Colorectal Surgery with Innovative Technology

The da Vinci SP system is designed to improve precision in surgeries that require access to narrow body cavities, such as those in the lower pelvis and rectum. By allowing surgeons to control up to three multi-jointed instruments and a high-definition articulating camera through a single entry point, the system offers enhanced freedom of movement in these smaller, more confined spaces.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive (Nasdaq: ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has announced its financial results for the first quarter of 2025, showcasing impressive growth and a strong strategic position in the healthcare technology market. The company's financial performance highlights robust growth in surgical procedures, system placements, and revenue, underscoring its leadership in the evolving field of robotic-assisted surgery.

Robust Growth in da Vinci Procedures and System Placements

In Q1 2025, Intuitive saw a 17% year-over-year increase in worldwide da Vinci procedures, reflecting the growing adoption of its robotic surgery systems. This increase is part of a broader trend towards minimally invasive surgery, where precision, reduced recovery times, and improved patient outcomes are driving demand.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive, a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), has published two groundbreaking studies highlighting the critical role of RAS in expanding access to high-quality care. These findings emphasize how robotic-assisted procedures contribute to improving patient outcomes, especially in medical deserts, and ultimately aid the growth of minimally invasive surgery (MIS), benefiting patients globally.

SHERIDAN, WYOMING – May 7, 2025 – Intuitive, a global leader in minimally invasive care and robotic-assisted surgery, has announced that its SureForm 45 stapler has received FDA clearance for use with the da Vinci SP surgical system. The stapler is now approved for thoracic, colorectal, and urology procedures, marking a significant milestone in robotic surgical technology.

This advancement allows surgeons to use the SureForm 45 stapler in single-port robotic surgeries, providing enhanced control and improved procedural efficiency. The FDA's clearance represents a major leap forward for Intuitive's continued innovation in surgical robotics and its commitment to reducing patient recovery times and enhancing surgical outcomes.

SHERIDAN, WYOMING – May 7, 2025 – Resmed (NYSE: RMD, ASX: RMD), a leading health technology company specializing in sleep, breathing, and home care, has announced the acquisition of VirtuOx, a prominent independent diagnostic testing facility (IDTF) focused on sleep, respiratory, and cardiac conditions. This strategic acquisition strengthens Resmed’s position in virtual care and reinforces its commitment to improving healthcare delivery by providing more accessible and coordinated care to patients and healthcare providers.

SHERIDAN, WYOMING – May 7, 2025 – Resmed Inc. (NYSE: RMD, ASX: RMD), a global leader in connected health solutions for sleep and respiratory care, has announced impressive third-quarter fiscal 2025 results. The company achieved a substantial year-over-year revenue growth of 8%, underscoring the continued demand for its innovative products and digital health solutions. With a focus on operational excellence and expanding its global footprint, Resmed has delivered a strong performance, further solidifying its position as a market leader in the healthcare sector.

SHERIDAN, WYOMING – May 7, 2025 – Resmed (NYSE: RMD, ASX: RMD), a global leader in health technology focused on sleep, breathing, and home care, has announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Schwartz brings over two decades of experience in leading investor engagement strategies at some of the world's leading health technology and financial services organizations. Her extensive background will be instrumental in advancing Resmed’s long-term strategic goals.

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX), a leader in medical technologies focused on women’s health, today announced its financial results for the second quarter of fiscal 2025. The company reported revenue of $1,005.3 million, slightly surpassing the upper end of its guidance, despite a decline in overall earnings per share (EPS) due to non-cash impairment charges. Hologic’s performance was primarily driven by strong demand in its diagnostics and skeletal businesses, along with ongoing profitability improvements and strategic share buybacks.

SHERIDAN, WYOMING – May 7, 2025 – Hologic, Inc. (Nasdaq: HOLX) is set to showcase its latest innovations in AI-driven mammography technology at the Society of Breast Imaging (SBI) Annual Symposium in Colorado Springs this week. A key highlight of the event will be the presentation of a pioneering study conducted at Massachusetts General Hospital, demonstrating the impact of Hologic's Genius AI® Detection Solution in improving breast cancer detection.

Revolutionary AI Mammography Technology

At the core of Hologic's presentation is a retrospective study involving 5,000 digital breast tomosynthesis (3D mammography) exams conducted between 2016 and 2019. This study focused on evaluating the performance of the Genius AI® Detection 2.0 mammography solution. Researchers analyzed screening results to determine the AI system’s ability to identify previously missed cancers and accurately detect and localize confirmed cases.